Table 2.
Femoral Trabecular Parameters: Anabolic Therapies
| Group | Femoral Tb.N | Femoral Tb.Th | Femoral Tb.Sp | |||
|---|---|---|---|---|---|---|
| VEH: WT/Nmp4−/− | 0.91 ± 0.23/1.18 ± 0.09 | 0.046 ± 0.006/0.045 ± 0.003 | 0.331 ± 0.023/0.285 ± 0.011 | |||
| PTH: WT/Nmp4−/− | 1.27 ± 0.17/1.99 ± 0.21 | 0.058 ± 0.002/0.065 ± 0.002 | 0.345 ± 0.038/0.264 ± 0.023 | |||
| PTH+ALN: WT/Nmp4−/− | 1.71 ± 0.43/1.96 ± 0.45 | 0.059 ± 0.004/0.063 ± 0.004 | 0.275 ± 0.020/0.263 ± 0.029 | |||
| PTH+ZOL: WT/Nmp4−/− | 2.07 ± 0.65/2.74 ± 0.47 | 0.072 ± 0.008/0.081 ± 0.006 | 0.282 ± 0.039/0.235 ± 0.034 | |||
| PTH+RAL: WT/Nmp4−/− | 2.16 ± 0.78/3.23 ± 0.49 | 0.075 ± 0.005/0.081 ± 0.008 | 0.263 ± 0.041/0.202 ± 0.032 | |||
| Anabolic therapy | G: | P < 0.0001 | G: | P < 0.0001 | G: | P < 0.0001 |
| T: | P < 0.0001 | T: | P < 0.0001 | T: | P < 0.0001 | |
| GxT: | P = 0.02 | GxT: | P = 0.0427 | GxT: | P = 0.0123 | |
| Nmp4−/− PTH+RAL | A | Nmp4−/− PTH+RAL | A | WT PTH | A | |
| Nmp4−/− PTH+ZOL | AB | Nmp4−/− PTH+ZOL | A | WT VEH | A | |
| WT PTH+RAL | BC | WT PTH+RAL | AB | Nmp4−/− VEH | B | |
| WT PTH+ZOL | C | WT PTH+ZOL | BC | WT PTH+ZOL | B | |
| Nmp4−/− PTH | C | Nmp4−/− PTH | CD | WT PTH+ALN | BC | |
| Nmp4−/− PTH+ALN | C | Nmp4−/− PTH+ALN | DE | Nmp4−/− PTH | BC | |
| WT PTH+ALN | CD | WT PTH+ALN | DE | WT PTH+RAL | BC | |
| WT PTH | DE | WT PTH | E | Nmp4−/− PTH+ALN | BC | |
| Nmp4−/− VEH | DE | Nmp4−/− VEH | F | Nmp4−/− PTH+ZOL | CD | |
| WT VEH | E | WT VEH | F | Nmp4−/− PTH+RAL | D | |
The micro-CT analyses of the femoral architecture in mice treated with the anabolic therapies. The data were analyzed using two-way analyses of variance using genotype and treatment as the independent variables. Statistical significance was set at P ≤ 0.05, and levels not connected by the same letter are significantly different. The data represent mean ± standard deviation, n = 7 to 12 mice per group.
Abbreviations: G, genotype; T, treatment.